Trial Profile
Phase II Study of Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs BCG (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 10 Apr 2024 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 10 Apr 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.
- 13 Jul 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm changed from 1 to 2 and study design changed from Single Group Assignment to Parallel Assignment.